NYSE:AGN - Allergan Stock Price, Forecast & News

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan declared a quarterly dividend on Friday, October 25th. Shareholders of record on Wednesday, November 13th will be given a dividend of $0.74 per share on Friday, December 13th. This represents a $2.96 annualized dividend and a yield of 1.59%. The ex-dividend date is Tuesday, November 12th. View Allergan's Dividend History.

Allergan announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, January 29th 2019, which allows the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to buy up to 4.1% of its shares through open market purchases. Shares buyback plans are often a sign that the company's board of directors believes its shares are undervalued.

Allergan plc (NYSE:AGN) issued its earnings results on Tuesday, November, 5th. The company reported $4.25 earnings per share for the quarter, hitting the Zacks' consensus estimate of $4.25. The company earned $4.03 billion during the quarter, compared to analyst estimates of $3.88 billion. Allergan had a negative net margin of 58.50% and a positive return on equity of 9.08%. The business's revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the business earned $4.25 EPS. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Allergan.

Allergan updated its FY19 earnings guidance on Tuesday, November, 5th. The company provided earnings per share guidance of >$16.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.74. The company issued revenue guidance of $15.6-15.8 billion, compared to the consensus revenue estimate of $15.58 billion.

20 brokerages have issued 1 year price objectives for Allergan's shares. Their forecasts range from $144.95 to $203.00. On average, they anticipate Allergan's share price to reach $175.90 in the next twelve months. This suggests that the stock has a possible downside of 5.8%. View Analyst Price Targets for Allergan.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 16 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

News coverage about AGN stock has been trending somewhat negative this week, according to InfoTrie. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Allergan earned a news sentiment score of -1.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Allergan.

Allergan saw a increase in short interest during the month of November. As of November 29th, there was short interest totalling 13,770,000 shares, an increase of 28.9% from the November 14th total of 10,680,000 shares. Based on an average trading volume of 2,330,000 shares, the days-to-cover ratio is presently 5.9 days. Currently, 4.2% of the company's shares are short sold. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Transocean (RIG) and United Rentals (URI).

Allergan's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (4.51%), Third Point LLC (1.10%), Assenagon Asset Management S.A. (0.54%), Boussard & Gavaudan Investment Management LLP (0.40%), Sachem Head Capital Management LP (0.39%) and Newport Trust Co (0.38%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Diamond Hill Capital Management Inc., State of New Jersey Common Pension Fund D, Robeco Institutional Asset Management B.V., Metropolis Capital Ltd, Russell Investments Group Ltd., Great West Life Assurance Co. Can, California State Teachers Retirement System and Envestnet Asset Management Inc.. View Insider Buying and Selling for Allergan.

AGN stock was bought by a variety of institutional investors in the last quarter, including Third Point LLC, State Street Corp, Assenagon Asset Management S.A., Boussard & Gavaudan Investment Management LLP, Sachem Head Capital Management LP, Canyon Capital Advisors LLC, York Capital Management Global Advisors LLC and Tibra Equities Europe Ltd. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $186.64.

Allergan has a market capitalization of $61.27 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]